Re: Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trials

Immune checkpoint inhibitors (ICIs) are revolutionary anticancer drugs approved in an expanding variety of cancer types [1]. ICIs restore the activity of the immune system and primarily of T cells to destroy neoplastic cells [1]. Currently, approved ICIs are monoclonal antibodies blocking cytotoxic T-lymphocyte –associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD1), which are immune checkpoint brakes expressed on T cells [1]. ICIs also include anti–PD-L1 (PD1 ligand located on cancer cells) normally interacting with PD1 to tone down T cells [1].
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Letter to the Editor Source Type: research